Company Profile
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Latest News
Dow Jones Futures Rise, Oil Prices Dive On Iran Hopes; Apple Leads Earnings Wave, Fed Meeting Ahead
China's industrial profit growth moderates as exports cushion uneven recovery
Shares, bonds make guarded gains as oil slips
The St. Regis Bali Resort Unveils the First Jack's Club in a Resort Setting with Live Jazz, Celebrated Mixologists, and Timeless Evening Rituals
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.roche.com |
| Market Cap | 286.84B |
| Trailing P/E | 23.47 |
| Forward P/E | 16.41 |
| Dividend Rate | 9.8 |
| Dividend Yield | 2.72% |
| Trailing Annual Div. Rate | 9.8 |
| Trailing Annual Div. Yield | 2.76% |
| Trailing EPS | 15.34 |
| Forward EPS | 21.94 |
| Book Value | 42.49 |
| Price-to-Book | 8.47 |
| Enterprise-to-Revenue | 4.99 |
| Enterprise-to-EBITDA | 13.12 |
| Ex-Dividend Date | 03/12/2026 |
| Dividend Date | 03/31/2025 |
| Earnings Date | |
| Earnings Call Date | |
| Revenue Average | 15.57B |
| Revenue Low | 15.42B |
| Revenue High | 15.71B |